Alan Horsager - Scopus Biopharma PresofImmunoOncology BioTherapeutics
| SCPSDelisted Stock | USD 0.10 0.00 0.00% |
Insider
Alan Horsager is PresofImmunoOncology BioTherapeutics of Scopus Biopharma
| Age | 50 |
| Phone | 212 479 2513 |
| Web | https://scopusbiopharma.com |
Scopus Biopharma Management Efficiency
The company has return on total asset (ROA) of (4.6089) % which means that it has lost $4.6089 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (15.596) %, meaning that it created substantial loss on money invested by shareholders. Scopus Biopharma's management efficiency ratios could be used to measure how well Scopus Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Scopus Biopharma currently holds 2.54 M in liabilities with Debt to Equity (D/E) ratio of 0.61, which is about average as compared to similar companies. Scopus Biopharma has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Scopus Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Scopus Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Scopus Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Scopus to invest in growth at high rates of return. When we think about Scopus Biopharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Yassine Bendiabdallah | Pasithea Therapeutics Corp | 40 | |
| Christopher Roenfeldt | Forte Biosciences | N/A | |
| MBA MD | Monopar Therapeutics | 38 | |
| Daniel Schneiderman | Pasithea Therapeutics Corp | 46 | |
| Andrew MBA | Monopar Therapeutics | 52 | |
| Jonathan MD | Erasca Inc | 52 | |
| Lisa TesvichBonora | Erasca Inc | N/A | |
| Antony CPA | Forte Biosciences | 57 | |
| Jesse Shefferman | Protara Therapeutics | 52 | |
| Tiago Marques | Pasithea Therapeutics Corp | 47 | |
| Hannah Fry | Protara Therapeutics | 33 | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| Chandra Lovejoy | Erasca Inc | 53 | |
| Scott CA | DiaMedica Therapeutics | 59 | |
| Wei MD | Erasca Inc | 54 | |
| David MD | Erasca Inc | 40 | |
| Steven Ruhl | Forte Biosciences | 67 | |
| Dominic Cundari | DiaMedica Therapeutics | 73 | |
| MD BA | Pasithea Therapeutics Corp | 76 | |
| CPA MS | Erasca Inc | 55 | |
| MBA MPH | Protara Therapeutics | 41 | |
Management Performance
| Return On Equity | -15.6 | ||||
| Return On Asset | -4.61 |
Scopus Biopharma Leadership Team
Elected by the shareholders, the Scopus Biopharma's board of directors comprises two types of representatives: Scopus Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Scopus. The board's role is to monitor Scopus Biopharma's management team and ensure that shareholders' interests are well served. Scopus Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Scopus Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ira Greenspan, Advisor Director | ||
| David Silberg, Advisor | ||
| Robert Gibson, S Chairman | ||
| Alan Horsager, PresofImmunoOncology BioTherapeutics |
Scopus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Scopus Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -15.6 | ||||
| Return On Asset | -4.61 | ||||
| Current Valuation | 1.18 M | ||||
| Shares Outstanding | 21.09 M | ||||
| Shares Owned By Insiders | 50.66 % | ||||
| Shares Owned By Institutions | 2.15 % | ||||
| Number Of Shares Shorted | 23.77 K | ||||
| Price To Book | 2.42 X | ||||
| EBITDA | (26.18 M) | ||||
| Net Income | (26.95 M) |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Scopus OTC Stock
If you are still planning to invest in Scopus Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Scopus Biopharma's history and understand the potential risks before investing.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |